Clinical Guidelines for Alcohol Use Disorder Continuity Care

Abstract

Alcohol Use Disorder (AUD) represents a major public health concern, characterized by high morbidity, mortality, and relapse rates. This review synthesizes current clinical guidelines and recent evidence on the continuity of care for AUD, emphasizing epidemiology, pathophysiology, risk factors, diagnostic criteria, management strategies, recent advances, and practical guideline-based recommendations. The article aims to provide healthcare professionals with an integrative understanding of continuity care approaches, highlighting mechanisms underpinning chronicity, risk stratification, and multifaceted interventions to optimize long-term outcomes for individuals with AUD.

Introduction

Alcohol Use Disorder is a chronic relapsing brain disease with pervasive clinical, psychological, and socioeconomic implications. Despite the availability of evidence-based interventions, AUD remains undertreated and often fragmented across healthcare systems. Continuity of care defined as coordinated, ongoing management has emerged as a critical paradigm for reducing relapse, enhancing recovery, and improving overall quality of life. This review critically appraises the latest clinical guidelines and scientific literature to inform optimal continuity care for AUD, focusing on evidence-based strategies that bridge acute treatment, rehabilitation, and long-term relapse prevention.

Epidemiology / Disease Burden

Globally, AUD affects over 280 million people, accounting for approximately 5% of the global disease burden and 3 million annual deaths, per WHO estimates. Prevalence rates vary with geographic, sociodemographic, and cultural factors, with higher incidence observed in high-income countries and among men. AUD is associated with a substantial range of comorbidities, including liver disease, cardiovascular disorders, neuropsychiatric conditions, and increased risk of injury. The chronic and relapsing nature of AUD results in high rates of healthcare utilization and significant economic impact, underscoring the need for structured, continuous care pathways.

Pathophysiology

AUD is underpinned by neurobiological alterations involving multiple neurotransmitter systems, notably gamma-aminobutyric acid (GABA), glutamate, dopamine, and endogenous opioid peptides. Chronic alcohol exposure leads to neuroadaptations that drive compulsive alcohol seeking, tolerance, withdrawal phenomena, and impaired control. Dysregulation of the mesolimbic reward circuitry, stress response pathways (including the hypothalamic-pituitary-adrenal axis), and neuroinflammation are central to the persistence and recurrence of AUD. Genetic predispositions and epigenetic modifications further modulate vulnerability and disease trajectory.

Risk Factors

Risk factors for AUD encompass genetic, psychological, and environmental domains. Family history confers a two- to four-fold increased risk, while early initiation of alcohol use, childhood adversity, and coexistent psychiatric disorders such as depression, anxiety, or ADHD significantly elevate susceptibility. Social determinants, including peer influence, socioeconomic deprivation, and community alcohol availability, also play critical roles. Clinical risk stratification tools and screening instruments facilitate targeted interventions for high-risk individuals within continuity care frameworks.

Clinical Features

Patients with AUD exhibit a spectrum of clinical manifestations, ranging from hazardous drinking to severe compulsive use associated with tolerance, withdrawal, and loss of control. Common features include preoccupation with alcohol, unsuccessful attempts to cut down, continued use despite harm, and neglect of occupational, social, or familial responsibilities. Physical signs may involve hepatomegaly, hypertension, neuropathy, and cognitive deficits. Psychiatric comorbidity is widespread, often complicating the clinical course and prognosis, necessitating integrated care approaches.

Diagnosis

Diagnosis is primarily clinical, guided by DSM-5 criteria, which require the presence of at least two out of eleven specified symptoms within a 12-month period. Validated screening instruments such as the Alcohol Use Disorders Identification Test (AUDIT) and CAGE questionnaire facilitate case identification. Laboratory investigations including liver function tests, carbohydrate-deficient transferrin, and gamma-glutamyl transferase assist in assessing chronicity and end-organ involvement. Differential diagnoses include other substance use disorders, mood disorders, and medical conditions with overlapping symptoms.

Treatment & Management

Continuity care in AUD integrates acute detoxification, rehabilitation, maintenance pharmacotherapy, psychosocial interventions, and relapse prevention. Medical management of withdrawal utilizes benzodiazepines, thiamine, and supportive care. Maintenance pharmacotherapies with robust evidence include naltrexone, acamprosate, and disulfiram, tailored to patient characteristics and comorbidities. Psychosocial modalities such as cognitive-behavioral therapy, motivational interviewing, contingency management, and 12-step facilitation underpin long-term recovery. Integrated care models address comorbid psychiatric and medical conditions, with case management and assertive outreach to maintain engagement and adherence.

Recent Advances / Emerging Therapies

Recent research has elucidated novel pharmacological targets, including neuroimmune modulation (e.g., ibudilast), kappa-opioid receptor antagonists, and corticotropin-releasing factor antagonists. Digital health interventions such as telemedicine, smartphone-based monitoring, and e-health platforms offer promising adjuncts to traditional care, particularly in enhancing continuity and accessibility. Personalized medicine approaches, utilizing pharmacogenomics and biomarker-guided therapy, are under investigation to optimize individual treatment responses and minimize adverse effects.

Guideline Recommendations

Leading international guidelines (e.g., APA, NICE, WHO) advocate for a chronic care model in AUD management. Core recommendations include systematic case finding, brief interventions, integrated medical and psychosocial treatment, regular monitoring for relapse, and seamless transitions across care settings. Multidisciplinary teams, including primary care, psychiatry, addiction specialists, and social services, are essential for comprehensive management. Collaborative care plans, shared decision-making, and patient-centered goal setting are emphasized to enhance adherence and recovery outcomes. Regular reassessment and flexibility in care intensity are vital to accommodate fluctuating patient needs over time.

Conclusion

Continuity care represents a pivotal standard in the management of Alcohol Use Disorder, addressing the complex interplay of biological, psychological, and social determinants that underpin chronicity and relapse. Evidence-based guidelines support integrated, multidisciplinary approaches encompassing pharmacological, psychosocial, and digital interventions tailored to individual risk profiles and clinical trajectories. Ongoing advances in neurobiology, therapeutics, and care delivery models hold promise for further optimizing outcomes. Sustained commitment to guideline-driven continuity care is imperative to mitigate the burden of AUD and improve long-term recovery for affected individuals.